Polyunsaturated Fatty Acid Levels and Your Genetics
By the ExomeDNA Research Team
This page contains general information only. For personal health decisions, consult a qualified clinician.
Polyunsaturated fatty acid levels reflect how your body absorbs, transports, and metabolizes essential fats from your diet — and genetics plays a meaningful role in shaping that profile. APOE, APOC1, ALDH1A2, DOCK7, and ZPR1 are among the genes associated with circulating PUFA concentrations. Below: what these fats do, the genes involved, what the research shows, and how to work with your result.
What is polyunsaturated fatty acid levels?
Polyunsaturated fatty acids (PUFAs) are a class of dietary fats characterized by multiple double bonds in their carbon chains. Unlike saturated fats, PUFAs cannot be manufactured by the body in meaningful quantities — they must come from food. The two principal families are omega-3 PUFAs (found in fatty fish, flaxseed, and walnuts) and omega-6 PUFAs (found in vegetable oils, nuts, and seeds). Both families are structurally essential: they form the phospholipid bilayers of every cell membrane, serve as precursors to signaling molecules called eicosanoids, and regulate inflammatory responses throughout the body.
What separates people is not simply how much PUFA they consume but how efficiently their bodies absorb, transport, convert, and incorporate those fats into tissues. Two people eating identical diets can end up with notably different circulating PUFA concentrations. That individual variation has a heritable component, and genome-wide association studies have identified several genetic loci — particularly in regions near APOE and APOC1 on chromosome 19 — that associate with measured plasma PUFA levels.
Your ExomeDNA result reflects the genetic factors that influence your baseline capacity to maintain circulating polyunsaturated fatty acid concentrations. It is not a direct measurement of your current PUFA levels.
The genetics behind polyunsaturated fatty acid levels
Several genes work in concert to determine how PUFAs move through your bloodstream and reach your tissues.
APOE is the most strongly associated gene for this trait. It encodes apolipoprotein E, a protein that coats lipoprotein particles — the vehicles that carry fats (including PUFAs) through the bloodstream. APOE binds to receptors on liver and peripheral cells, directing the uptake and clearance of triglyceride-rich particles such as chylomicrons and VLDL. Different APOE isoforms (commonly referred to as E2, E3, and E4 variants) differ in how efficiently they mediate this clearance. The E4 isoform is associated with less efficient clearance of PUFA-carrying lipoprotein remnants, which can affect how much dietary fatty acid reaches cell membranes versus remains circulating in plasma. Because omega-3 PUFAs like DHA are critical structural components of brain cell membranes, APOE's influence on PUFA transport has been studied in the context of both cardiovascular and neurological health.
APOC1, located near APOE on chromosome 19q13, encodes apolipoprotein C1. This small protein is expressed primarily in the liver and acts as an inhibitor of lipoprotein lipase (LPL) — the enzyme responsible for breaking down triglycerides in VLDL and chylomicrons and releasing fatty acids into tissues. APOC1 also inhibits cholesteryl ester transfer protein (CETP). Together, these inhibitory effects modulate how much PUFA is released from circulating particles into peripheral tissues. Variants near APOC1 can shift the balance of PUFA delivery toward or away from storage versus immediate tissue uptake.
ALDH1A2 encodes retinaldehyde dehydrogenase 2 (RALDH2), an enzyme responsible for converting retinaldehyde into retinoic acid. While its primary role is in retinoid metabolism, ALDH1A2 also processes certain oxidized fatty acid aldehydes — byproducts of lipid peroxidation. Its appearance in PUFA-associated genetic studies likely reflects a shared metabolic regulatory environment in the liver: retinoic acid, produced by ALDH1A2, signals through retinoic acid receptors (RAR/RXR) that in turn regulate the expression of enzymes involved in PUFA elongation and desaturation. In this way, the retinoic acid pathway and the PUFA metabolism pathway are intertwined at the transcriptional level.
DOCK7 encodes a guanine nucleotide exchange factor (GEF) that activates Rac1 and Cdc42 — proteins involved in cell signaling and cytoskeletal dynamics. It is expressed in both liver and brain tissue. Within hepatocytes, DOCK7 may influence lipid droplet dynamics and intracellular fatty acid handling, potentially affecting how efficiently PUFAs are processed after delivery from the bloodstream.
ZPR1, a zinc finger protein expressed in the liver, has been associated with triglyceride levels in multiple genetic studies. It appears to influence lipid metabolism gene expression in hepatocytes, and its association with circulating fatty acid levels may reflect downstream effects on VLDL assembly and secretion — the pathway through which PUFA-laden particles enter the bloodstream from the liver.
What the research says
Research base: Moderate. The genetic architecture of circulating PUFA levels has been examined in metabolomic studies that measure hundreds of plasma metabolites simultaneously, including fatty acid species. Genetic signals near APOE and APOC1 appear consistently across lipid and metabolomic analyses. However, for this specific trait — fasting plasma polyunsaturated fatty acid levels — the GWAS evidence base currently rests on a limited number of studies, which is why the confidence tier for this trait is moderate rather than robust.
A 2021 study by Li-Gao and colleagues (PMID 34610981) examined genetic associations with changes in metabolite levels following a standardized liquid meal challenge. This postprandial metabolomics design provides a different window into fatty acid metabolism than standard fasting measurements: it captures how the genome influences dynamic responses to dietary fat intake, not just baseline concentrations. The study illuminated novel genetic pathways connecting lipoprotein biology to measured fatty acid levels, with signals near established lipid-metabolism loci reinforcing the role of APOE-region variants.
Two points of context for interpreting the research:
Omega-3 vs. omega-6 distinction matters. Population-level PUFA studies often measure total PUFA or separate omega-3 and omega-6 fractions. The health implications of these two families differ substantially — and sometimes point in opposite directions. Genetic variants that raise total PUFA do not necessarily favor the omega-3 fraction.
Plasma levels vs. tissue incorporation. Circulating PUFA concentrations are measurable and heritable, but the biologically relevant quantity for brain and cardiac function is often the degree of PUFA incorporation into cell membranes — particularly the ratio of DHA (an omega-3) in phospholipids. Plasma levels and membrane content correlate imperfectly, and genetics influences both steps independently.
References Li-Gao R et al. (2021). Genetic Studies of Metabolomics Change After a Liquid Meal Illuminate Novel Pathways. PMID: 34610981.
Data sources: GWAS Catalog, Open Targets, ClinVar, dbSNP, NCBI Gene.
How polyunsaturated fatty acid levels affects you
Polyunsaturated fatty acids are not simply nutrients — they are the raw material for structures and signals that run throughout the body. The downstream effects of your PUFA metabolism profile touch several interconnected systems.
Cell membrane composition. Every cell in your body is bounded by a phospholipid bilayer, and the proportion of PUFAs embedded in that bilayer affects membrane fluidity, receptor function, and the efficiency of ion channels. Neurons are particularly sensitive to membrane PUFA content: DHA (an omega-3) makes up roughly 15-20% of the fatty acid content in brain gray matter. Membrane composition influences how quickly synaptic signals are transmitted and how efficiently neurotransmitter receptors operate.
Inflammatory signaling. Omega-6 PUFAs — particularly arachidonic acid — are metabolized into pro-inflammatory eicosanoids (prostaglandins, leukotrienes, thromboxanes). Omega-3 PUFAs produce anti-inflammatory resolvins and protectins instead. The balance between these two families in your tissues shapes your body's inflammatory setpoint. Genetics that favors lower PUFA clearance or altered PUFA-to-lipid particle ratios can shift which family predominates in circulating and membrane pools.
Cardiovascular context. The APOE and APOC1 region is one of the most extensively studied loci in cardiovascular genetics. APOE isoform differences affect LDL cholesterol, triglyceride clearance, and cardiovascular event rates in observational research. PUFA-carrying lipoproteins travel the same metabolic highways, meaning that genetic variation in this region affects not just PUFA delivery but the broader lipoprotein landscape relevant to heart health.
The omega-6:omega-3 ratio. Research consistently shows that the ratio between these two families — not the absolute level of either — is the more informative marker. Traditional hunter-gatherer diets maintained a ratio close to 4:1 (omega-6 to omega-3). Contemporary Western dietary patterns produce ratios of 15:1 to 20:1, driven by widespread use of omega-6-rich vegetable oils. Genetic variation in PUFA transport and metabolism can either widen or narrow this ratio at the tissue level, independent of dietary intake.
Brain aging and APOE. The APOE gene's influence on PUFA metabolism intersects with its well-documented role in brain aging research. DHA, the primary omega-3 in brain tissue, relies on lipoprotein transport mechanisms that APOE mediates. Differences in APOE isoform-dependent DHA delivery to neurons have been studied in the context of cognitive aging and neuroinflammation, with E4 carriers showing different plasma and membrane DHA profiles compared to E2 and E3 carriers.
Working with your polyunsaturated fatty acid levels result
Your result describes the genetic factors that influence your baseline PUFA metabolism — not a fixed ceiling on your PUFA status. Diet, supplementation, and lifestyle choices interact with your genetic profile. The following steps are ranked by evidence and practicality:
Prioritize marine omega-3 sources. Fatty fish (salmon, sardines, mackerel, herring) deliver EPA and DHA directly in their active form, bypassing any conversion step. Two to three servings per week is a widely cited dietary benchmark for cardiovascular and anti-inflammatory benefit in mainstream nutritional research.
Add plant-based omega-3 sources. Flaxseed, chia seeds, and walnuts provide ALA (alpha-linolenic acid), the dietary precursor to EPA and DHA. Conversion efficiency from ALA to EPA/DHA is modest in humans (typically under 10% for DHA), so plant sources complement but do not fully replace marine sources for tissue-level DHA delivery.
Consider EPA+DHA supplementation. Fish oil or algae-based omega-3 supplements (EPA+DHA) at 1-3 grams per day are among the best-studied dietary supplements for cardiovascular outcomes. Algae-derived DHA is the source used in infant formula and provides the same molecular form found in fish. This option is relevant for those who do not consume fish regularly.
Audit omega-6 intake. Reducing consumption of omega-6-rich refined vegetable oils (corn, soybean, sunflower) in favor of olive oil or avocado oil measurably shifts the dietary omega-6:omega-3 ratio without requiring supplementation. This single dietary swap has outsize effects on the balance of fatty acids available for membrane incorporation.
Follow a Mediterranean dietary pattern. The Mediterranean diet — emphasizing olive oil, fatty fish, legumes, vegetables, nuts, and limited refined carbohydrates — consistently produces favorable PUFA ratios in dietary intervention studies. It is not a PUFA supplement strategy but a dietary architecture that naturally optimizes the omega-3:omega-6 balance across meal patterns.
Track omega-3 status with blood testing. Omega-3 index testing (measuring EPA+DHA as a percentage of total red blood cell fatty acids) provides a direct readout of tissue-level omega-3 incorporation independent of genetics. It is available through several direct-to-consumer lab services and provides a functional complement to your ExomeDNA genetic result.
Consult a registered dietitian for personalized guidance. Genetic results for PUFA metabolism are most useful when interpreted alongside actual dietary intake patterns, lipid panel results, and any relevant personal or family health history. A registered dietitian with nutrition-genomics experience can help integrate these data sources.
Related traits and genes
Polyunsaturated fatty acid levels sit at the intersection of several related genetic traits available in your ExomeDNA report. Understanding them together gives a more complete picture of your metabolic and cardiovascular lipid profile.
Within the Nutrition and Metabolism category:
- Triglyceride Levels — APOC1 and ZPR1 variants influence triglyceride levels and PUFA transport through overlapping mechanisms.
- Omega-3 Index — Captures EPA+DHA-specific genetic associations, the omega-3 fraction of total PUFA.
- LDL Cholesterol Levels — APOE isoform differences that shape PUFA clearance also drive LDL variation.
Cross-category connections:
- Inflammatory Response — Omega-6:omega-3 balance feeds eicosanoid synthesis pathways, linking PUFA genetics to Immune and Inflammatory Health traits.
- Cardiovascular Health Score — APOE and APOC1 are core cardiovascular loci; PUFA metabolism is one input into polygenic cardiovascular risk.
The APOE gene's isoform structure (E2, E3, E4) influences lipoprotein metabolism, cardiovascular risk, and brain aging. See the APOE gene page for isoform-level detail.
Frequently asked questions
Are higher PUFA levels better or worse?
The answer depends on which PUFAs are elevated. Higher omega-3 PUFA levels — particularly EPA and DHA — are generally associated with anti-inflammatory effects, favorable cardiovascular biomarkers, and better membrane composition in neurons and heart cells. Higher omega-6 PUFA levels without a corresponding rise in omega-3s can shift the body toward a more pro-inflammatory state. Your ExomeDNA result describes your genetic profile for total circulating PUFA levels; the omega-3:omega-6 balance within that total is equally important to consider.
Does my APOE variant change how I should eat?
APOE isoforms influence how efficiently your body clears fat-carrying lipoproteins after meals. Research in this area has examined whether people with different APOE variants respond differently to dietary fat composition — with some studies suggesting that APOE4 carriers may see larger effects of saturated fat intake on LDL cholesterol. For omega-3s specifically, APOE isoform differences have been associated with variation in how much DHA reaches brain tissue. A clinician or registered dietitian familiar with nutrigenomics can help you weigh these considerations for your specific situation.
Can I improve my PUFA levels through diet even if my genetics are unfavorable?
Yes. Genetics shapes your baseline tendencies, but dietary intake remains a primary driver of circulating PUFA levels. The conversion efficiency from dietary ALA to active EPA and DHA, and the clearance of PUFA-carrying lipoproteins, all respond to dietary patterns. Consistent omega-3-rich food choices and reduction of excess omega-6 from refined oils move circulating and membrane PUFA status in measurable ways for most people, regardless of genetic background.
What is the omega-6:omega-3 ratio and why does it matter?
The omega-6:omega-3 ratio describes the relative proportion of these two PUFA families in your diet and tissues. Omega-6 PUFAs (primarily linoleic acid and arachidonic acid) favor pro-inflammatory eicosanoid production; omega-3 PUFAs (EPA and DHA) favor anti-inflammatory resolvins and protectins. Research on traditional dietary patterns suggests ratios near 4:1 (omega-6 to omega-3). Contemporary Western diets average 15:1 to 20:1. Genetics that influences PUFA transport or clearance can affect which family is more available at the tissue level, but diet is the dominant driver of the ratio for most people.
Is the PUFA genetics result the same as a blood test for omega-3 levels?
No. Your ExomeDNA result describes genetic variants associated with plasma polyunsaturated fatty acid concentrations — it reflects your inherited tendencies, not your current measured levels. A blood test (such as an omega-3 index test measuring EPA+DHA in red blood cell membranes) provides a direct measurement of your current omega-3 status, shaped by both your genetics and your recent dietary choices. Both types of information are useful; they answer different questions.
How does ALDH1A2 connect to fatty acid metabolism?
ALDH1A2 is primarily known for producing retinoic acid from retinaldehyde, but it also processes certain oxidized fatty acid byproducts. More broadly, retinoic acid — produced by ALDH1A2 — activates nuclear receptors (RAR and RXR) that regulate the genes encoding fatty acid desaturases and elongases, the enzymes that convert short-chain PUFAs into their longer, more biologically active forms like EPA and DHA. ALDH1A2's presence in PUFA-associated genetic studies likely reflects this shared regulatory network in liver metabolism, where retinoid and fatty acid pathways are co-regulated.
ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.
References
Li-Gao R et al. (2021). Genetic Studies of Metabolomics Change After a Liquid Meal Illuminate Novel Pathways. PMID: 34610981.
Data sources: GWAS Catalog, Open Targets, ClinVar, dbSNP gene annotations, NCBI Gene summaries.